Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study [Phase 2]
Phase 2 clinical trial NCT04445844 (IRENE study) combines INCMGA00012 with Pelareorep for metastatic triple-negative breast cancer; the stud…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer [Phase 2, Phase 3]
A clinical trial update describes a neoadjuvant regimen for triple-negative breast cancer using paclitaxel polymeric micelles and carboplati…
-
CLINICAL_TRIALS research · 2025-03-26Clinical Trial Update: Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer [EARLY_Phase 1]
This early-phase trial is studying a neoadjuvant combination of dupilumab, pembrolizumab, paclitaxel, and carboplatin in locally advanced tr…
-
CLINICAL_TRIALS research · 2025-03-26Clinical Trial Update: Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) [Phase 3]
Clinical trial update for CITRINE, a Phase 3 study evaluating intensified chemotherapy with carboplatin for triple-negative breast cancer.
-
CLINICAL_TRIALS research · 2025-03-26Clinical Trial Update: A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC [Phase 2]
Phase 2 clinical trial evaluating camrelizumab plus nab-paclitaxel and levocetirizine for metastatic or recurrent triple-negative breast can…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors [Phase 2]
Phase 2 study evaluating pembrolizumab in patients with advanced solid tumors, including squamous cell carcinoma of the head and neck, tripl…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer [Phase 2]
A multicenter, prospective Phase 2 cohort trial evaluating Trop-2 antibody-drug conjugate combination therapy for advanced triple-negative b…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 study of Sacituzumab Govitecan in Japanese participants with advanced solid tumors is ongoing, including metastatic triple-negativ…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer [Phase 1, Phase 2]
This document reports the results of a Phase 1/2 clinical trial evaluating the combination of palbociclib and binimetinib in patients with a…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC [Phase 2]
Phase II trial of chiauranib in combination with capecitabine for triple-negative breast cancer was terminated. The update notes the study s…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients [Phase 3]
An ongoing Phase 3 trial evaluating the efficacy and safety of nanosomal docetaxel lipid suspension in patients with triple-negative breast …
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating a novel neoadjuvant and adjuvant strategy for patients with germline BRCA1/2-mutated triple-negative breas…
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy [Phase 1, Phase 2]
An ongoing Phase 1/Phase 2 clinical trial is investigating how circadian rhythm affects responses to neoadjuvant immunotherapy in triple-neg…
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC [Phase 3]
Phase 3 trial update for PM8002 or placebo plus Nab-Paclitaxel as first-line therapy in inoperable locally advanced or metastatic triple-neg…
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: A Multicenter Cancer Biospecimen Collection Study
A multicenter cancer biospecimen collection trial sponsored by Cofactor Genomics is currently recruiting, covering multiple cancer indicatio…
-
CLINICAL_TRIALS research · 2025-03-11Clinical Trial Update: A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC [Phase 1, Phase 2]
Clinical trial update for PM8002 plus Nab-paclitaxel as first-line therapy in triple-negative breast cancer; the study is currently ACTIVE_N…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer [Phase 2]
Phase 2 trial update of AZD5363 (Capivasertib) in combination with paclitaxel for triple-negative and metastatic breast cancer has completed…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC [Phase 2]
Phase 2 clinical trial update indicates the addition of ipatasertib to neoadjuvant chemotherapy plus atezolizumab for triple-negative breast…
-
CLINICAL_TRIALS research · 2025-03-06Clinical Trial Update: Study of LP-184 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Lantern Pharma's LP-184 is being studied in a phase 1/2 trial for advanced and metastatic solid tumors, with indications including glioblast…
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. [Phase 2]
This is a Phase 2 clinical trial evaluating Trop2-ADC as monotherapy or in combination with immunotherapy for metastatic triple-negative bre…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC [Phase 2]
Phase 2 study evaluating first-line treatment of relapsed or metastatic triple-negative breast cancer using albumin-bound paclitaxel in comb…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer [Phase 2]
This is a Phase 2 adjuvant trial evaluating dynamic biomarker–adjusted personalized therapy to optimize risk assessment and therapy response…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial using HIM typing to guide first-line treatment for advanced triple-negative breast cancer; the study is currently n…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer [Phase 2]
Phase 2 clinical trial update evaluating correlation between clinical response and pathologic response in patients with early breast cancer.
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) [Phase 2]
This Phase 2 trial evaluates CMP-001 in combination with pre-operative SBRT for early-stage triple-negative breast cancer and is currently a…